SRR1313165
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.500
- ALLOGRAFT_REJECTION+0.470
- INTERFERON_GAMMA_RESPONSE+0.440
- INFLAMMATORY_RESPONSE+0.390
- TNFA_SIGNALING_VIA_NFKB+0.380
- INTERFERON_ALPHA_RESPONSE+0.370
- MTORC1_SIGNALING+0.320
- IL2_STAT5_SIGNALING+0.300
- MYC_TARGETS_V1+0.300
- PANCREAS_BETA_CELLS+0.300
Top 10 suppressed
- MITOTIC_SPINDLE-0.180
- UV_RESPONSE_DN-0.100
- DNA_REPAIR-0.070
- MYOGENESIS-0.050
- ESTROGEN_RESPONSE_EARLY+0.000
- NOTCH_SIGNALING+0.000
- TGF_BETA_SIGNALING+0.040
- APICAL_SURFACE+0.050
- FATTY_ACID_METABOLISM+0.070
- XENOBIOTIC_METABOLISM+0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-ZF-AA53-01A-11R-A39I-07 | — | — | 0.911 |
| 2 | MNG380 | — | — | 0.906 |
| 3 | TCGA-C8-A26X-01A-31R-A16F-07 | — | C | 0.906 |
| 4 | MNG1029 | — | — | 0.905 |
| 5 | TCGA-UY-A78P-01A-12R-A36F-07 | — | — | 0.894 |
| 6 | TCGA-ZF-A9RD-01A-11R-A42T-07 | — | — | 0.876 |
| 7 | TCGA-FD-A5C1-01A-11R-A28M-07 | — | — | 0.874 |
| 8 | BS_9HSGV9TJ | pleomorphic xanthoastrocytoma(PXA) | — | 0.872 |
| 9 | DRR168574 | — | — | 0.871 |
| 10 | MDT-AP-2506 | Med | Medulloblastoma | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| HYPOXIA | 0.230 | Idelalisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |